Our top pick for
Neoleukin Therapeutics, Inc is a drug manufacturers-specialty & generic business based in the US. Neoleukin Therapeutics shares (NLTX) are listed on the NASDAQ and all prices are listed in US Dollars. Neoleukin Therapeutics employs 65 staff and has a market cap (total outstanding shares value) of USD$498.2 million.
|52-week range||USD$5.81 - USD$18.13|
|50-day moving average||USD$13.114|
|200-day moving average||USD$12.5906|
|Wall St. target price||USD$22.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.938|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-15.94%|
|Return on equity TTM||-21.51%|
|Market capitalisation||USD$498.2 million|
TTM: trailing 12 months
There are currently 3.2 million Neoleukin Therapeutics shares held short by investors – that's known as Neoleukin Therapeutics's "short interest". This figure is 7.7% up from 3.0 million last month.
There are a few different ways that this level of interest in shorting Neoleukin Therapeutics shares can be evaluated.
Neoleukin Therapeutics's "short interest ratio" (SIR) is the quantity of Neoleukin Therapeutics shares currently shorted divided by the average quantity of Neoleukin Therapeutics shares traded daily (recently around 244580.15209125). Neoleukin Therapeutics's SIR currently stands at 13.15. In other words for every 100,000 Neoleukin Therapeutics shares traded daily on the market, roughly 13150 shares are currently held short.
However Neoleukin Therapeutics's short interest can also be evaluated against the total number of Neoleukin Therapeutics shares, or, against the total number of tradable Neoleukin Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neoleukin Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Neoleukin Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0898% of the tradable shares (for every 100,000 tradable Neoleukin Therapeutics shares, roughly 90 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Neoleukin Therapeutics.
Find out more about how you can short Neoleukin Therapeutics stock.
We're not expecting Neoleukin Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Neoleukin Therapeutics's shares have ranged in value from as little as $5.81 up to $18.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neoleukin Therapeutics's is 1.0043. This would suggest that Neoleukin Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.